Literature DB >> 2608564

The cost of chronic dialysis in multiple myeloma.

R A Coward1.   

Abstract

The complications and costs of chronic dialysis in 4 patients with renal failure due to multiple myeloma are presented. In three patients the paraprotein responded to chemotherapy though without recovery of renal function. These three patients are alive after 18, 16 and 15 months of dialysis, the other dying after 7 months. Hospital admissions ranged from 26 to 74 days per year with infections accounting for 54 to 87% of admission days, 62.5% of which occurred during the first three months of dialysis treatment, with an incidence of 2.4 to 6.9 admissions episodes per year. An in-house audit of our chronic dialysis patients indicated that treatment of myeloma patients is 5-33% more expensive. The extra cost in such high risk patients is mostly due to the greater number and longer duration of hospital admissions for infection. The other extra costs (in decreasing value) of blood products, antibiotics and chemotherapy are relatively small in comparison to in-patient treatment.

Entities:  

Mesh:

Year:  1989        PMID: 2608564      PMCID: PMC2429306          DOI: 10.1136/pgmj.65.763.302

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  17 in total

1.  INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA.

Authors:  J L FAHEY; R SCOGGINS; J P UTZ; C F SZWED
Journal:  Am J Med       Date:  1963-11       Impact factor: 4.965

2.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

3.  Infections complicating multiple myeloma and chronic lymphocytic leukemia.

Authors:  J J Twomey
Journal:  Arch Intern Med       Date:  1973-10

4.  Dialysis in the treatment of multiple myeloma.

Authors:  W J Johnson; R A Kyle; P J Dahlberg
Journal:  Mayo Clin Proc       Date:  1980-02       Impact factor: 7.616

5.  Multi-centre study on outcome of treatment in patients on continuous ambulatory peritoneal dialysis and haemodialysis.

Authors:  R Gokal; R Baillod; S Bogle; L Hunt; C Jakubowski; F Marsh; C Ogg; D Oliver; M Ward; R Wilkinson
Journal:  Nephrol Dial Transplant       Date:  1987       Impact factor: 5.992

6.  Multiple myeloma: review of 869 cases.

Authors:  R A Kyle
Journal:  Mayo Clin Proc       Date:  1975-01       Impact factor: 7.616

Review 7.  Immunosuppression and infection in multiple myeloma.

Authors:  D R Jacobson; S Zolla-Pazner
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

8.  Should patients with renal failure associated with myeloma be dialysed?

Authors:  R A Coward; N P Mallick; I W Delamore
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-26

9.  Influence of treatment and response status on infection risk in multiple myeloma.

Authors:  R T Perri; R P Hebbel; M M Oken
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

10.  Severe renal failure in multiple myeloma.

Authors:  F G Cosio; T V Pence; F L Shapiro; C M Kjellstrand
Journal:  Clin Nephrol       Date:  1981-04       Impact factor: 0.975

View more
  1 in total

1.  Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Beth M Faiman; Patricia Mangan; Jacy Spong; Joseph D Tariman
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.